SEC Form 4 · accession 0001209191-16-142451
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William D Baird III
Officer — Chief Financial Officer
Period of report
Sep 20, 2016
Accepted (ET)
Sep 22, 2016 · 4:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 20, 2016 | M | 3,500 | $8.00 | A | 56,450 | D | |
| Common Stock | Sep 20, 2016 | S | 3,500 | $8.00 | D | 52,950 | D | |
| Common StockF3 | Sep 20, 2016 | S | 17,000 | $8.0044 | D | 35,950 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy) | $2.45 | Sep 20, 2016 | M | 3,500 | D | Jan 3, 2015 | Jan 3, 2024 | Common Stock | 3,500 | 34,000 | D |
Explanation of responses
- F1The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2016
- F2The sale of shares of common stock were made pursuant to a J.P. Morgan Securities LLC Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2016
- F3This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $8.00 to $8.04. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.